TERT and urinary bladder cancer: By contrast, the cost of the NGS-based and ddPCR assays for detecting urinary TERT promoter mutations in bladder cancer developed by our group [10,11] is about 24€ per sample, and, therefore, has the potential to be easily implemented for cost-effective bladder cancer management strategies.